JP2023529214A5 - - Google Patents
Info
- Publication number
- JP2023529214A5 JP2023529214A5 JP2022575977A JP2022575977A JP2023529214A5 JP 2023529214 A5 JP2023529214 A5 JP 2023529214A5 JP 2022575977 A JP2022575977 A JP 2022575977A JP 2022575977 A JP2022575977 A JP 2022575977A JP 2023529214 A5 JP2023529214 A5 JP 2023529214A5
- Authority
- JP
- Japan
- Prior art keywords
- approximately
- epha2
- cancer
- tumor tissue
- staining assay
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063038279P | 2020-06-12 | 2020-06-12 | |
| US63/038,279 | 2020-06-12 | ||
| PCT/GB2021/051451 WO2021250418A1 (en) | 2020-06-12 | 2021-06-11 | Treatment of diseases characterized by overexpression of erythropoietin-producing hepatocellular receptor a2 (epha2) |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023529214A JP2023529214A (ja) | 2023-07-07 |
| JP2023529214A5 true JP2023529214A5 (cg-RX-API-DMAC7.html) | 2024-06-19 |
Family
ID=76641715
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022575977A Pending JP2023529214A (ja) | 2020-06-12 | 2021-06-11 | エリスロポエチン産生肝細胞受容体ａ２（ｅｐｈａ２）の過剰発現を特徴とする疾患の治療 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230233698A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4165414A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2023529214A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230065231A (cg-RX-API-DMAC7.html) |
| CN (1) | CN115698720A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021289095A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3180095A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL298868A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2022015419A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021250418A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ731185A (en) | 2014-10-29 | 2024-03-22 | Bicyclerd Ltd | Bicyclic peptide ligands specific for mt1-mmp |
| WO2019002842A1 (en) | 2017-06-26 | 2019-01-03 | Bicyclerd Limited | BICYCLIC PEPTIDE LIGANDS WITH DETECTABLE FRACTIONS AND USES THEREOF |
| JP7670481B2 (ja) | 2017-08-04 | 2025-04-30 | バイスクルテクス・リミテッド | Ｃｄ１３７に対して特異的な二環式ペプチドリガンド |
| GB201721265D0 (en) | 2017-12-19 | 2018-01-31 | Bicyclerd Ltd | Bicyclic peptide ligands specific for EphA2 |
| TWI825046B (zh) | 2017-12-19 | 2023-12-11 | 英商拜西可泰克斯有限公司 | Epha2特用之雙環胜肽配位基 |
| CA3091775A1 (en) | 2018-02-23 | 2019-08-29 | Bicycletx Limited | Multimeric bicyclic peptide ligands |
| US11180531B2 (en) | 2018-06-22 | 2021-11-23 | Bicycletx Limited | Bicyclic peptide ligands specific for Nectin-4 |
| GB201810316D0 (en) | 2018-06-22 | 2018-08-08 | Bicyclerd Ltd | Peptide ligands for binding to EphA2 |
| GB201820295D0 (en) | 2018-12-13 | 2019-01-30 | Bicyclerd Ltd | Bicyclic peptide ligands specific for MT1-MMP |
| GB201820288D0 (en) | 2018-12-13 | 2019-01-30 | Bicycle Tx Ltd | Bicycle peptide ligaands specific for MT1-MMP |
| GB201820325D0 (en) | 2018-12-13 | 2019-01-30 | Bicyclerd Ltd | Bicyclic peptide ligands specific for psma |
| WO2020128527A1 (en) | 2018-12-21 | 2020-06-25 | Bicyclerd Limited | Bicyclic peptide ligands specific for pd-l1 |
| EP3897849A1 (en) | 2018-12-21 | 2021-10-27 | BicycleTx Limited | Bicyclic peptide ligands specific for pd-l1 |
| GB201900529D0 (en) | 2019-01-15 | 2019-03-06 | Bicycletx Ltd | Bicyclic peptide ligands specific for CD38 |
| KR20220007098A (ko) | 2019-05-09 | 2022-01-18 | 바이사이클티엑스 리미티드 | Ox40에 특이적인 이환식 펩티드 리간드 |
| TWI860386B (zh) | 2019-07-30 | 2024-11-01 | 英商拜西可泰克斯有限公司 | 異質雙環肽複合物 |
| CN116348476A (zh) | 2020-08-03 | 2023-06-27 | 拜斯科技术开发有限公司 | 基于肽的接头 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0607450A2 (pt) * | 2005-02-04 | 2009-09-01 | Raven Biotechnologies Inc | anticorpos que se ligam a epha2 e métodos para sua utilização |
| CN101918844A (zh) * | 2007-06-18 | 2010-12-15 | 米迪缪尼有限公司 | 表达epha2和erbb2的细胞的协同治疗 |
| EP2223112A2 (en) * | 2007-12-21 | 2010-09-01 | Siemens Healthcare Diagnostics Inc. | Circulating epha2 receptor |
| JP6074574B2 (ja) | 2008-02-05 | 2017-02-08 | バイシクル セラピューティクス リミテッド | 方法及び組成物 |
| CA2847245A1 (en) * | 2011-09-09 | 2013-03-14 | Amgen Inc. | Use of c-met protein for predicting the efficacy of anti-hepatocyte growth factor ("hgf") antibodies in esophageal and gastric cancer patients |
| WO2016171242A1 (ja) * | 2015-04-24 | 2016-10-27 | 第一三共株式会社 | Ｅｐｈａ２の検出 |
| JP2019512477A (ja) * | 2016-03-16 | 2019-05-16 | メリマック ファーマシューティカルズ インコーポレーティッド | エフリン受容体ａ２（ｅｐｈａ２）のナノリポソーム標的化及び関連する診断 |
| TWI825046B (zh) | 2017-12-19 | 2023-12-11 | 英商拜西可泰克斯有限公司 | Epha2特用之雙環胜肽配位基 |
| GB201721265D0 (en) | 2017-12-19 | 2018-01-31 | Bicyclerd Ltd | Bicyclic peptide ligands specific for EphA2 |
| CN109700812A (zh) * | 2019-01-18 | 2019-05-03 | 厦门大学 | 一种治疗表达parp10的肝细胞癌的药物组合物及其应用 |
| US20220184222A1 (en) * | 2019-04-02 | 2022-06-16 | Bicycletx Limited | Bicycle toxin conjugates and uses thereof |
| CN114760988A (zh) * | 2019-11-27 | 2022-07-15 | 拜斯科技术开发有限公司 | 对EphA2具有特异性的双环肽配体和其用途 |
-
2021
- 2021-06-11 EP EP21735361.4A patent/EP4165414A1/en active Pending
- 2021-06-11 US US18/001,374 patent/US20230233698A1/en active Pending
- 2021-06-11 CA CA3180095A patent/CA3180095A1/en active Pending
- 2021-06-11 KR KR1020237001004A patent/KR20230065231A/ko active Pending
- 2021-06-11 CN CN202180042177.6A patent/CN115698720A/zh active Pending
- 2021-06-11 AU AU2021289095A patent/AU2021289095A1/en active Pending
- 2021-06-11 IL IL298868A patent/IL298868A/en unknown
- 2021-06-11 WO PCT/GB2021/051451 patent/WO2021250418A1/en not_active Ceased
- 2021-06-11 JP JP2022575977A patent/JP2023529214A/ja active Pending
- 2021-06-11 MX MX2022015419A patent/MX2022015419A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023538906A5 (cg-RX-API-DMAC7.html) | ||
| ES3047748T3 (en) | Using alternating electric fields to increase cell membrane permeability | |
| Kesharwani | Nanotechnology-based targeted drug delivery systems for lung cancer | |
| Lammertink et al. | Increase of intracellular cisplatin levels and radiosensitization by ultrasound in combination with microbubbles | |
| Silver et al. | Current trends in initial management of laryngeal cancer: the declining use of open surgery | |
| Shimizu et al. | Nicotine promotes lymph node metastasis and cetuximab resistance in head and neck squamous cell carcinoma | |
| Moser et al. | Targeting HSP90 by the novel inhibitor NVP-AUY922 reduces growth and angiogenesis of pancreatic cancer | |
| JP2010523680A5 (cg-RX-API-DMAC7.html) | ||
| Zhao et al. | Inhibition of cell proliferation and induction of autophagy by KDM2B/FBXL10 knockdown in gastric cancer cells | |
| Liu et al. | Enhancing autophagy by down-regulating GSK-3β alleviates cisplatin-induced ototoxicity in vivo and in vitro | |
| RU2016141385A (ru) | Лечение рака антагонистами с-мет и их корреляция с экспрессией hgf | |
| Mao et al. | P-glycoprotein targeted and near-infrared light-guided depletion of chemoresistant tumors | |
| Dueñas-González et al. | Multimodal treatment of locally advanced cervical cancer | |
| Zhitomirsky et al. | The role of cytoplasmic-to-lysosomal pH gradient in hydrophobic weak base drug sequestration in lysosomes | |
| Mouawad et al. | The antitumor drug F14512 enhances cisplatin and ionizing radiation effects in head and neck squamous carcinoma cell lines | |
| BR112020026382A2 (pt) | combinações de poziotinibe com um anticorpo anti-her1, her2 ou her4 e métodos de uso das mesmas | |
| Yule et al. | Combination of bemcentinib (BGB324): a first-in-class selective oral AXL inhibitor, with pembrolizumab in patients with triple negative breast cancer and adenocarcinoma of the lung | |
| CN106580942B (zh) | 壬二酸在制备抗急性髓系白血病和化疗增敏药物中的应用 | |
| Dai et al. | Progress in the treatment of peritoneal metastatic cancer and the application of therapeutic nanoagents | |
| Gunka et al. | Long-term results of laparoscopic versus open surgery for nonmetastatic colorectal cancer | |
| Ramalingam et al. | Molecularly-targeted therapies for non-small cell lung cancer | |
| Chen et al. | Folate decoration of exosomes directs tumor-specific delivery of celastrol for the treatment of hepatocellular carcinoma | |
| RU2626682C1 (ru) | Способ прогнозирования резистентности опухоли к таргетной терапии цетуксимабом у больных плоскоклеточным раком языка и слизистой дна полости рта | |
| RU2534410C2 (ru) | Способ определения чувствительности злокачественной опухоли к химиопрепарату | |
| Karmanova et al. | Possible Applications of Azurin, a Copper-Containing Protein, in Cancer Treatment: Prospects and Challenges |